NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016, 68019 [2016-23719]
Download as PDF
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 81, No. 191 / Monday, October 3, 2016 / Notices
in the survey is voluntary. Although the
names of the participating entities might
be disclosed in the summary memo and
the memo might contain information
provided to the Board for internal use
only, exemption 4 of the Freedom of
Information Act (5 U.S.C. 552(b)(4)) may
exempt this information from disclosure
to the public. However, if the
information collected on the FR 1374
does not meet these standards for
confidentiality (for example if the
information collected is already public),
it would not be granted confidential
treatment.
2. Report title: Domestic Finance
Company Report of Consolidated Assets
and Liabilities.
Agency form number: FR 2248.
OMB control number: 7100–0005.
Frequency: Monthly, quarterly, and
semi-annually.
Respondents: Domestic finance
companies and mortgage companies.
Estimated number of respondents:
450.
Estimated average hours per response:
Monthly, 20 minutes; Quarterly, 30
minutes; Addendum, 10 minutes.
Estimated annual burden hours: 750
hours.
General Description of Report: The FR
2248 is collected monthly as of the last
calendar day of the month from a
stratified sample of finance companies.
Each monthly report collects balance
sheet data on major categories of
consumer and business credit
receivables and on major short-term
liabilities. For quarter-end months
(March, June, September, and
December), additional asset and liability
items are collected to provide a full
balance sheet. A supplemental section
collects data on securitized assets. The
data are used to construct universe
estimates of finance company holdings,
which are published in the monthly
statistical releases Finance Companies
(G.20) and Consumer Credit (G.19), in
the quarterly statistical release Flow of
Funds Accounts of the United States
(Z.1), and in the Federal Reserve
Bulletin (Tables 1.51, 1.52, and 1.55).
Legal authorization and
confidentiality: The Board’s Legal
Division has determined that the FR
2248 is authorized by law pursuant to
Section 2A of the Federal Reserve Act,
12 U.S.C. 225a). The obligation to
respond is voluntary. Individual
respondent data are confidential under
section (b)(4) of the Freedom of
Information Act (5 U.S.C. 552(b)(4)).
VerDate Sep<11>2014
17:56 Sep 30, 2016
Jkt 241001
Board of Governors of the Federal Reserve
System, September 28, 2016.
Robert deV. Frierson,
Secretary of the Board.
[FR Doc. 2016–23781 Filed 9–30–16; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[CDC–2015–0034, Docket Number NIOSH
233–A]
NIOSH List of Antineoplastic and Other
Hazardous Drugs in Healthcare
Settings 2016
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of issuance of final
guidance publication.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
announces the availability of the
following publication: NIOSH List of
Antineoplastic and Other Hazardous
Drugs in Healthcare Settings 2016
[2016–161].
ADDRESSES: This document may be
obtained at the following link: https://
www.cdc.gov/niosh/docs/2016-161/.
FOR FURTHER INFORMATION CONTACT:
Barbara A. MacKenzie, NIOSH Division
of Applied Research and Technology,
1090 Tusculum Avenue, MS C–26,
Cincinnati, OH 45226. 513–533–8132
(not a toll free number), bmackenzie@
cdc.gov.
SUMMARY:
Dated: September 27, 2016.
Frank Hearl,
Chief of Staff, National Institute for
Occupational Safety and Health, Centers for
Disease Control and Prevention.
[FR Doc. 2016–23719 Filed 9–30–16; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
68019
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Questions—PQ2.
Date: October 20, 2016.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
6W030, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Zhiqiang Zou, MD, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, 9609 Medical
Center Drive, Room 7W242, Rockville, MD
20892–9750, 240–276–6372, zouzhiq@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Regional Centers of Research,
Excellence in Non-Communicable
Diseases in Low and Middle Income
Countries.
Date: October 25, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Shamala K. Srinivas,
Ph.D., Scientific Review Officer, Office
of Referral, Review and Program
Coordination, Division of Extramural
Activities, National Cancer Institute,
9609 Medical Center Drive, Room
7W530, Rockville, MD 20892–9750,
240–276–5856, ss537t@nih.gov
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Innovative Molecular Analysis
Technologies (IMAT).
Date: October 27–28, 2016.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda,
8120 Wisconsin Avenue, Bethesda, MD
20814.
Contact Person: Reed A. Graves,
Ph.D., Scientific Review Officer,
Research and Technology and Contract
Review Branch, Division of Extramural
Activities, National Cancer Institute,
9609 Medical Center Drive, Room
E:\FR\FM\03OCN1.SGM
03OCN1
Agencies
[Federal Register Volume 81, Number 191 (Monday, October 3, 2016)]
[Notices]
[Page 68019]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23719]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[CDC-2015-0034, Docket Number NIOSH 233-A]
NIOSH List of Antineoplastic and Other Hazardous Drugs in
Healthcare Settings 2016
AGENCY: National Institute for Occupational Safety and Health (NIOSH),
Centers for Disease Control and Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of issuance of final guidance publication.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC),
announces the availability of the following publication: NIOSH List of
Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016
[2016-161].
ADDRESSES: This document may be obtained at the following link: https://www.cdc.gov/niosh/docs/2016-161/.
FOR FURTHER INFORMATION CONTACT: Barbara A. MacKenzie, NIOSH Division
of Applied Research and Technology, 1090 Tusculum Avenue, MS C-26,
Cincinnati, OH 45226. 513-533-8132 (not a toll free number),
bmackenzie@cdc.gov.
Dated: September 27, 2016.
Frank Hearl,
Chief of Staff, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2016-23719 Filed 9-30-16; 8:45 am]
BILLING CODE 4163-19-P